Across TCGA pan-cancer cohorts, CAMK2G Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated CAMK2G data layer compared with 26 for mass-spec protein and 4 for mass-spec protein.
The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher CAMK2G Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated CAMK2G expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.
UCEC and MESO are the cancer types where CAMK2G Mutation most reproducibly stratifies survival.